Weyerhaeuser - Lots...
Health Care: Drugs
Ligand Pharmaceuticals Inc. (LGND: NASDAQ)
$31.43 -1.48 | -4.50%
06/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 31.43 |
| 52 Week High | 33.86 |
| 52 Week Low | 14.75 |
| Avg. Daily Vol. (Mil) | 0.18 |
| Beta (3 year) | 1.29 |
| Share Related Items | |
| Mkt Cap (Mil) | 635.98 |
| Shares Out (Mil) | 20.23 |
| Float (Mil) | 14.22 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.40 |
| Current Ratio | 0.50 |
| LT Debt/ Equity | 0.35 |
| Total Debt / Equity | 0.88 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 17.00 |
| Price/Book | 20.79 |
| Price/Cash Flow | 215.00 |
| Per Share Data | |
| Earnings | 0.01 |
| Sales | 1.85 |
| Book Value | 1.51 |
| Cash Flow | 0.15 |
| Business Summary | |
|---|---|
| Ligand Pharmaceuticals, Inc., is a biotechnology company that operates with a business model focused on developing or acquiring assets. | |
| General Information | |
| 11119 North Torrey Pines Roa
Suite 200 La Jolla, CA 92037 |
|
| www.ligand.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 21 | |
| CEO: Mr. John L. Higgins | |
| Short Interest | |
| Current Month (Mil) | 2.00 |
| Previous Month (Mil) | 1.90 |
| Short Interest Ratio (Days) | 11.60 |
| Management Effectiveness | |
| Return on Equity | 0.30 |
| Return on Assets | 0.10 |
| Return on Investments | 0.20 |
| Profitability | |
| Gross Margin | 96.70 |
| EBIT Margin | 5.30 |
| Profit Margin | 0.30 |
Portfolios with LGND
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserGFNN Stockdiagnostics 6
- ContributorStocks With Big Insider Buy...
Latest LGND Headlines from TheStreet
- Ligand Pharmaceuticals Inc. Stock Downgraded (LGND) 02.18.13 | 04:02 am
- 5 Hated Stocks Set to Soar on Earnings 02.12.13 | 12:02 pm
- 5 Stocks Insiders Are Scooping Up 01.30.13 | 12:01 pm
- Top Insider Trades: BAC LGND PCRX BDBD 01.28.13 | 08:01 am
- 7 Stocks Rising on Unusual Volume 01.09.13 | 02:01 pm
- The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo
11.30.12 | 05:11 am - 6 Stocks Rising on Unusual Volume 11.19.12 | 03:11 pm
- Stocks Under $10: Blossoming Biotech Play 09.25.12 | 06:09 am
- Onyx's Kyprolis Cancer Drug Approved 07.20.12 | 12:07 pm
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 07.13.12 | 07:07 pm
Press Releases for LGND
- Ligand Signs Global License Agreement With Spectrum Pharmaceuticals For Captisol-Enabled® Melphalan - Business Wire 03.14.13 | 07:03 am
- Ligand Receives $1.4 Million Milestone Payment From Retrophin, Inc. - Business Wire 02.25.13 | 09:02 am
- Ligand Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.13.13 | 04:02 pm
- Ligand To Report Fourth Quarter Results On February 13th - Business Wire 01.23.13 | 09:01 am
- Ligand Receives Equity Milestone Payment From Retrophin - Business Wire 01.09.13 | 09:01 am
- U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis - Business Wire 12.13.12 | 05:12 pm
- U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis - Business Wire 12.13.12 | 05:12 pm
- Ligand Initiates Pivotal Trial Of Captisol-Enabled®, Propylene Glycol-Free Melphalan In Patients With Multiple Myeloma - Business Wire 12.10.12 | 04:12 pm
- Ligand To Present Growth Prospects, Review Key Portfolio Assets And Introduce Financial Guidance At Analyst Day Event - Business Wire 12.04.12 | 08:12 am
- Reminder: Ligand To Host Analyst Day On December 4th In New York City - Business Wire 11.27.12 | 09:11 am
Partner Headlines for LGND
- Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication - Benzinga 11.19.12 | 09:11 am
- Ligand Pharma Announces Preclinical Data for LG-7501 - Benzinga 11.13.12 | 09:11 am
- The Medicines Co. Halts MDCO-2010 - Analyst Blog - Zacks 10.08.12 | 06:10 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Netflix REITERATED Below Average and 3 Analyst-Reiterated Ratings Starting the Week - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- DJIA Weekly Review: Back-to-School Forecast Warms Up, GE and Chevron Craft Deal - Wall St. Cheat Sheet 07.22.12 | 10:07 am
- Healthcare Business Recap: Onyx's Drug Gets APPROVED, Somaxon DIVESTS Shares - Wall St. Cheat Sheet 07.20.12 | 11:07 am
- Pfizer Review ACCEPTED and 4 Stocks Enjoying 52-Week Highs - Wall St. Cheat Sheet 07.20.12 | 09:07 am
- 3M SETTLES Suit and 3 Dow Movers to Watch - Wall St. Cheat Sheet 07.19.12 | 05:07 am
- Jim Cramer Calls: Sell HP and 'Buy, Buy, Buy' These Hot Stocks Now - Wall St. Cheat Sheet 07.16.12 | 10:07 am
